Release of fowlpox virus (FWPV) as extracellular enveloped virus (EEV
Introduction
Poxviruses are among the largest and most complex viruses known. Vaccinia virus (VV), the prototypic member of the genus Orthopoxvirus, is the most studied poxvirus. Viruses of the genus Avipoxvirus, of which fowlpox virus (FWPV) is the prototypic member, have received considerable attention since their development as safe, non-replicating vectors for vaccination of mammals, including man, because of their narrow host range (reviewed by Limbach & Paoletti, 1996) .
Little is known about the morphogenesis of FWPV, compared to the extensively studied VV maturation process. VV replication occurs entirely in the cytoplasm of infected cells. The first viral structures detectable by electron microscopy are crescent-shaped structures formed around the viroplasm in the virus factories. These structures develop into spherical immature virions (IV), which subsequently mature into characteristic brick-shaped particles, called intracellular mature virions (IMV), which are infectious. The membranes of these IMVs were first thought to be synthesized de novo (Dales & Mosbach, 1968) but it was later suggested that they were derived from the intermediate compartment between the endoplasmic reticulum and the cis-Golgi cisternae and consisted of two lipid bilayers (Sodeik et al., 1993) . A recent study using high resolution electron microscopy showed, however, that the crescents, the IV and IMV particles contain only a single lipid bilayer that does not show continuity with any preexisting cellular membrane (Hollinshead et al., 1999) . The mechanism of formation of these membranes is, however, still unknown. The fate of the IMV seems to vary depending on the strain of virus, the type of cells and the time post-infection (Ichihashi et al., 1971 ; Payne & Kristenson, 1979) . They can either : (i) remain in the cell until cellular lysis, (ii) bud through the plasma membrane (Tsutsui, 1983 ; Tsutsui et al., 1983) or (iii) acquire an additional double membrane by wrapping (Dales, 1963 ; Ichihashi et al., 1971 ; Morgan, 1976 ; Tooze et al., 1993) . The two additional membranes acquired by wrapping derive either from the tubular early endosomes (Tooze et al., 1993) or from the trans-Golgi network (TGN) (Schmelz et al., 1994) . This unusual mechanism of envelopment is used not only by poxviruses but also by herpesviruses (Tooze et al., 1993) . The intracellular enveloped virions (IEV), formed after wrapping, migrate to the cell surface where the external membrane of the virus fuses with the plasma membrane, releasing extracellular infectious enveloped virions, EEV (Dales, 1963 ; Ichihashi et al., 1971 ; Morgan, 1976 ; Payne & Kristenson, 1979) . This migration can be facilitated by formation of actin tails, propelling IEV particles at the tip of microvilli (Cudmore et al., 1995 ; Hiller et al., 1979 ; Ichihashi et al., 1971 ; Stokes, 1976 ; Tsutsui et al., 1983) , increasing the efficiency of cell-to-cell spread (Roper et al., 1998 ; Sanderson et al., 1998) . A proportion of virions leaving the cell, referred to as cell-associated enveloped virus (CEV), remain associated with the outside of the plasma membrane (Blasco & Moss, 1992 ; . By electron microscopy, FWPV IMV morphogenesis is similar to that of VV (Arhelger & Randall, 1964) . The mechanism of production of extracellular particles, antigenically different to intracellular particles (Maiti et al., 1991) , is less clear.
EEV particles acquire a number of viral proteins specifically associated with the extra envelope. VV genes encoding six of them have been identified : A33R (Roper et al., 1996) , A34R (Duncan & Smith, 1992) , A36R (Parkinson & Smith, 1994) , A56R (Shida, 1986) , B5R (Engelstad et al., 1992 ; Isaacs et al., 1992) and F13L (Hirt et al., 1986) . Deleting the genes encoding these proteins, followed by characterization of the mutants, has been used for studying the role these proteins play in egress. Four EEV proteins, B5R (Engelstad & Smith, 1993 ; Wolffe et al., 1993) , F13L (Blasco & Moss, 1991) and the A33R (Roper et al., 1998) and A34R (Wolffe et al., 1997) gene products, as well as the 14 kDa protein (A27L) present on the IMV envelope (Rodriguez & Smith, 1990) , have so far been shown to be essential for efficient wrapping and production of IEV. However, the few IEV produced by B5R and F13L deletion mutants are able to induce actin tails, while A33R and A34R deletion mutants are unable to do so (Rottger et al., 1999) . The other two EEV proteins, A56R and A36R, are both nonessential for IEV production (Sanderson et al., 1998 ; but, whereas A56R is also non-essential for actin tail formation, A36R is essential and seems to be critical for actin tail formation, alone or in association with A34R (Rottger et al., 1999 ; Sanderson et al., 1998 ; Wolffe et al., 1998) . The efficiency of formation of IEV does not correlate necessarily with the amount of EEV produced, as the A33R (Roper et al., 1998) and A34R (McIntosh & Smith, 1996) deletion mutants produce even more EEV than the wild-type virus.
The A34R gene product, predicted to be a type II membrane protein with homology to C-type animal lectins (Smith et al., 1991) , is apparently involved in regulating the release of progeny virions from the surface of infected cells, perhaps by binding to a carbohydrate component (Blasco et al., 1993) .
An FWPV homologue (p43K) of the F13L gene has been reported (Calvert et al., 1992) , deletion of which also affects the release of EEV (Calvert et al., 1992) . Interestingly, disruption of the FWPV F12L homologue also results in reduced EEV production (Ogawa et al., 1993) , but the F12L gene product has not yet been studied in VV and it is not known whether it is present in the EEV envelope. No homologues of other EEV proteins have so far been reported in FWPV. Because of this lack of markers, we investigated the release of FWPV by another approach used previously with VV. This involved the use of different chemicals that specifically block the production of EEV, either by inhibiting the wrapping process or by interfering with the release of the enveloped virus. N "
-isonicotinoyl-N # -3-methyl-4-chlorobenzoylhydrazine (IMCBH) has been shown to inhibit selectively the release of EEV particles, intracellular virus production being only slightly reduced (Kato et al., 1969) . This effect was shown to depend on the virus strain and the host-cell type (Kato et al., 1969) and to result from a blockage in wrapping (Payne & Kristenson, 1979) . The mechanism of action of IMCBH is not yet understood. Other drugs have also been shown to inhibit wrapping, such as monensin, brefeldin A and inhibitors of glycosylation such as 2-deoxy--glucose and glucosamine. The last two were shown to reduce the production of infectious virus, affecting EEV production rather than IMV production, with glucosamine being more efficient than 2-deoxy--glucose (Payne & Kristensson, 1982 b ; Weintraub et al., 1977) . Monensin, a carboxylic ionophore known to perturb the Golgi causing a dilation of the cisternae, blocking the transport of secreted proteins and O-glycosylation, had the same effect . Brefeldin A, an inhibitor of vesicular transport between the ER and the cis-Golgi, has been shown to inhibit specifically the formation of EEV, also by inhibiting wrapping (Ulaeto et al., 1995) . Cytochalasin D, a potent inhibitor of actin microfilament formation, was shown to prevent EEV release from the cell surface , suggesting that actin filaments are essential for the final release of EEV from the cell surface.
Methods
Virus and cells. FWPV FP9 strain was grown on chicken embryo fibroblasts (CEFs) in the presence of 2 % new born calf serum (NBCS).
WR-VTN, a WR VV recombinant containing the porcine transmissible gastroenteritis virus nucleoprotein inserted into the thymidine kinase gene (Pulford & Britton, 1990) , was grown under the same conditions as FWPV and was kindly provided by Paul Britton (IAH, Compton, UK).
Drugs. IMCBH was kindly provided by R. Wittek (Switzerland), as a 10 mg\ml stock in DMSO. Monensin, glucosamine, brefeldin A and cytochalasin D were purchased from Sigma. Monensin (0n1 M in methanol), cytochalasin D (10 mg\ml in DMSO) and brefeldin A (5 mg\ml in 75 % ethanol) stock solutions were stored at k20 mC. Glucosamine solutions were prepared freshly.
Electron microscopy. CEFs were infected with FP9 (1 p.f.u. per cell) and fixed in situ with 2n5% 0n1 M phosphate-buffered glutaraldehyde at different times post-infection (p.i.). Samples were then processed for transmission electron microscopy as described previously (Boulanger et al., 1998) .
Production of cell-associated virus (CAV) and extracellular virus (EV) in the presence of inhibitors. CEFs were inoculated in triplicate with FWPV FP9, or with VV recombinant WR-VTN as a control, at an m.o.i. of 0n01 or 1 p.f.u. in M199 medium supplemented with 2 % NBCS and containing 0, 5, 10 or 20 µg\ml IMCBH. Three days p.i., or 24 h p.i. depending on the m.o.i. used, the supernatant was removed, clarified by centrifugation at 1000 g for 10 min and stored at k70 mC until titration. The monolayers were covered with fresh medium and freeze-thawed once before titration.
Experiments using other drugs were performed by infecting CEFs with FWPV or with VV at an m.o.i. of 1 p.f.u. per cell in M199 medium supplemented with 2 % NBCS. Three hours p.i. the medium was removed and replaced by fresh medium containing 2 % NBCS and supplemented with 0n1 or 10 µM monensin ; 0, 5 or 20 mM glucosamine ; 0, 0n1 or 1 µg\ml cytochalasin D (in triplicate). Brefeldin A, at a concentration of 0, 50 or 500 ng\ml, was added 12 h p.i. in medium containing 4 % foetal calf serum (FCS). Twenty-four hours p.i., the supernatant was removed, clarified and stored at k70 mC until titration. The monolayers were covered with fresh medium and freeze-thawed once before titration.
In all cases, the triplicate samples were titrated on CEFs cultured in six-well plates.
Virus purification. Confluent CEFs were infected with FP9 at an m.o.i. of 1 p.f.u.. Forty-eight hours p.i., the supernatant was harvested (the EEV fraction), the monolayers washed once with PBS and dispersed by addition of trypsin. The cell suspension was spun 10 min at 1000 g after neutralizing the trypsin with 10 % NBCS. The supernatant was harvested (the CEV fraction) and the cell pellet resuspended in PBS before being submitted to one cycle of freeze-thawing (the IMV fraction). All fractions were clarified for 30 min at 1000 g. Supernatants were harvested and the virions were pelleted by centrifugation at 40 000 g for 1 h. The pellets were resuspended in TMN buffer (10 mM Tris pH 7n5, 1n5 mM MgCl # , 10 mM NaCl) and centrifuged 2 h at 160 000 g through a 25 % (w\w) sucrose cushion in TMN buffer. Pellets were resuspended in 1 ml TMN buffer and sonicated mildly before being layered over a preformed CsCl gradient (2n5 ml of 1n3 g\ml, 3n75 ml of 1n25 g\ml, 5 ml of 1n2 g\ml) and centrifuged at 182 000 g for 1 h. Fractions (0n5 ml) were collected from the bottom of the tube. The absorbance at 280 nm and the density of each fraction were measured.
Immunofluorescence microscopy. CEFs, seeded in chamber slides (Nunc) at 2i10& cells\ml of M199 medium supplemented with 10 % FCS, were infected with FWPV FP9 (m.o.i. of 2). After various periods of incubation the cells were fixed in acetone. Cells were treated with RNase A (3 mg\ml in PBS) for 1 h at 37 mC. After three washes in PBS the DNA was labelled overnight at 4 mC with propidium iodide (PI ; 50 µg\ml in PBS). After three washes with PBS the cells were blocked for 1 h at 4 mC with BSA (10 mg\ml in PBS). Actin was detected with a specific MAb (Sigma) and a fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse antibody (DAKO). Slides were mounted under DAKO Fluorescent Mounting Medium. Immunofluorescence was observed and recorded using a Leika TCS NT confocal microscope. The resulting images were processed with the Adobe Photoshop program.
Results

Morphogenesis of FWPV in CEFs : electron microscopy observations
At 12 h p.i., a few small virus factories containing crescents and a few isolated IV were observed. By 16 h p.i., the virus factories had increased in size and contained more IV (Fig. 1 A) . From 16 to 66 h p.i., the vast majority of viral particles were IV but all the subsequent steps of morphogenesis were also observed. Up to 47 h p.i., only a few isolated IMV were present ; some of them were partially ( Fig. 1 B, C) or completely wrapped, like VV. From 47 h p.i. onwards, IMV particles were also found in clusters associated with membranes near the virus factories. Typical wrapping of isolated IMV was rarely observed, even early post-infection. In contrast, from 20 h p.i. onwards, a lot of viral particles were accumulating close to the plasma membrane, some of them clearly budding through it (Fig. 2) . From these observations it seemed that FWPV, unlike VV, exits the cell predominantly by budding and not by wrapping and fusion.
Effect of IMCBH on virus production
If FWPV does exit the cell predominantly by budding instead of wrapping and fusion, we could assume that the chemicals known to inhibit these later steps in VV morphogenesis would not alter FWPV EEV production. In a first experiment, FWPV and VV were grown at a low m.o.i. on CEFs in the presence of different concentrations of IMCBH. EV and CAV were collected 3 days p.i. In these highly sensitive conditions, the titre of VV EV was reduced by 3 logs in the presence of only 5 µg\ml IMCBH, compared to the control grown without drug, and the titre of the CAV by 2 logs in the presence of the same concentration of inhibitor (Fig. 3) . Contrasting with those results, neither CAV nor EV titres of FWPV were affected by up to 20 µg\ml IMCBH [there was no statistical difference, as determined by the ANOVA one-way test, calculated on the log values : P l 0n009 and 0n04 for CAV and EV, respectively, with a residual degree of freedom (rdf) of 8] (Fig. 3) . The decrease of VV CAV titre was due to the sensitive conditions of this experiment, i.e. a low m.o.i. and a long duration of infection allowing several cycles of replication to occur. Using an m.o.i. of 1 in a control experiment, VV CAV titre was not affected by up to 20 µg\ml IMCBH whereas the EV titre decreased by 1 log (data not shown). Under the same conditions, FWPV was not affected by the drug (P l 0n05 and 0n27 for CAV and EV, respectively, with an rdf l 6).
Comparison between VV 37 kDa protein and FWPV p43K protein
The lack of effect of IMCBH on FWPV replication could either be explained by the use of another mechanism to produce extracellular particles or by the absence of a target for the drug in FWPV-infected cells. The IMCBH target has been identified in VV as the 37 kDa EEV envelope protein encoded by the F13L gene. A single mutation of nucleotide 927 from G to T, mutating the Asp-280 residue to a Tyr, confers resistance to IMCBH (Schmutz et al., 1991) . The sequence of the VV protein is extremely well conserved in different strains (Copenhagen, WR, L-IVP and IHD-J ; accession nos p20638, p04021, p29885 and p26653 respectively), with only one amino acid different between each of these strains (data not shown). A homologue of this protein exists in FWPV and seems also very well conserved in this genus as there is 100 % amino acid identity between the FP9 strain sequence (data not shown) and the large plaque variant described by Calvert et al. (1992) (accession no. a44216). The same group also published the sequence of two-thirds of the homologous ORF in pigeonpox virus (accession no. s27933) and found it had 100 % amino acid identity with the FWPV corresponding sequence. The homology between the VV protein (Copenhagen strain) and the FWPV protein calculated by the GCG GAP programme, under the GCG default settings, is 38 % amino acid identity and 49 % amino acid similarity. The alignment of the IHD-J protein, the IMCBH-resistant IHD-J clone 23 described by Schmutz et al. (1991) (accession no. M60413) and the FWPV protein (Fig. 4) shows that the critical Asp-280 residue is replaced by a Lys residue in the FWPV protein. The lack of effect of IMCBH on FWPV EV production could, therefore, be due to this mutation and does not necessarily imply a different mechanism of exit for FWPV.
Effects of glucosamine, monensin and brefeldin A on virus production
Investigation of the exit of FWPV was pursued by studying the effect of several drugs, reported previously to inhibit GHI Release of fowlpox virus Release of fowlpox virus (C) Closer view of an IMV particle budding through the plasma membrane at 47 h p.i. Magnifications : (A) i27 000 (inset i51 000) ; (B) i60 000 ; (C) i170 000.
specifically VV EEV particle production by inhibiting wrapping. Production of neither FWPV CAV nor EV was affected by addition of glucosamine (P l 0n08 and 0n43 respectively with an rdf l 6) (Fig. 5) . The VV control was affected by glucosamine but the effect was not specific to EV production : the CAV titre was decreased more (down to 14 % in the presence of 20 mM glucosamine) than the EV titre (down to 50 % in the same conditions) (Table 1) .
Monensin, up to a concentration of 10 µM, had no significant effect on the FWPV EV titre (P l 0n59 and 0n24 in two independent experiments both with an rdf l 6) ( monensin was due to a toxic effect of monensin on the cells. To reduce this toxic effect, the experiment was repeated by adding the drug 12 h p.i. for a duration of 12 h and pooling the cells pelleted from the supernatant fraction with the freeze-thawed cellular lysate. The difference in the CAV titres with or without drug was then reduced (P l 0n006 instead of 0n0001 with an rdf l 6), showing that this reduction of CAV titre was most likely due only to the toxicity of the drug rather than to a specific effect. Unexpectedly, VV was not affected by monensin, which did not have any effect on the production of VV EV in the control experiment (P l 0n96 with an rdf l 5 and see Table 1 ). This drug, under these conditions, therefore had no specific effect on the release of either FWPV or VV EV particles. A concentration of 5 µM monensin can, however, affect Golgi function in CEFs, as it blocks the secretion of viral proteins such as FWPV CEL1 glycoprotein (Stephen Laidlaw, personal communication).
Concentrations of brefeldin A higher than 0n1 µg\ml were toxic for CEFs when they were incubated in its presence for 24 h. The cells lost their characteristic morphology, became rounded and then detached. Brefeldin A was, therefore, added only 12 h p.i. like monensin. In these conditions neither CAV nor EV production was affected in the presence of up to 500 ng\ml brefeldin A (Fig. 5 ) (P l 0n04 and 0n74 respectively with an rdf l 6). VV was also not affected by brefeldin A under these conditions (Table 1) . . CAV (hatched bars) and extracellular (black bars) virus were harvested 24 h p.i. In each individual experiment the effect of one drug was tested in triplicate. Titres of the triplicate samples were determined by plaque assay. The histograms were drawn using the mean of the triplicate sample values. The error bars show the standard deviation. The difference between the titre of CAV and EV obtained without drug (panels A and C for instance) does vary, between 0n9 for the intracellular virus and 1n5 log10 for the EV. We cannot fully explain this variation between experiments though it may be due to differences between batches of CEFs.
Effect of cytochalasin D on virus production
In the presence of cytochalasin D at a concentration of 1 µg\ml the titres of FWPV and VV EV were slightly reduced (both down to about 20 % ; see Table 1 ), whereas the CAV titres were not affected (P l 0n82 and 0n004, respectively, for FWPV CAV and EV titres, with an rdf l 6).
Cytochalasin D reduces the release of CEV from infected cells
To check whether the reduction of the EV titre was due to an inhibition of release of EEV particles from the cell surface as described for VV or due to an inhibition of the production or migration to the cell surface of IEV particles, FWPV was grown on CEFs in the presence of 1 µg\ml cytochalasin D (or in the absence of the drug as a control) and the different types of particles produced were analysed by purification on CsCl gradients. In the presence of cytochalasin D, the EEV peak was reduced whereas the CEV peak was increased (Fig. 6 C-F) . Each peak showed the characteristic density for each type of particle. The intracellular fraction did not seem to contain an increased level of IEV (Fig.  6B) .
Reorganization of actin filaments due to FWPV infection
The effect of cytochalasin D suggests the involvement of actin in the release of FWPV, as shown for VV . Actin localization was identified by immunofluorescence in infected and uninfected cells. In noninfected cells, actin is either spread homogeneously in the cytoplasm, or forms stress fibres or long filaments, located mostly just beneath the plasma membrane (Fig. 7 D) . In FWPVinfected cells, the actin was reorganized into a punctate pattern and also concentrated into a region close to the nucleus (Fig.  7 A) , identified as the virus factory by the presence of DNA stained with PI (Fig. 7 B) . The PI staining also showed a punctate pattern (Fig. 7 B) shown, in the merged picture (Fig.  7 C) , to co-localize with the punctate actin staining. Table 1 . Effect of different drugs on infectious cell-associated and extracellular virus production expressed as the mean % of the control As the variation between experiments is not taken into account in this representation, results can be misleading if they are not interpreted in association with the error bars shown in Fig. 5 
Discussion
Electron microscopic observation of FWPV strain FP9 morphogenesis in CEFs showed it to be similar to that of VV in mammalian cell lines. Like VV, FWPV intracellular particles can be wrapped by cellular vesicles or tubules but they can also bud through the plasma membrane. Based on the observed frequency of budding, this mechanism seems to be the predominant way for FWPV to exit the cell, at least in our conditions using the FP9 strain grown on CEFs. In contrast, according to the literature, VV seems to exit predominantly by wrapping, and budding would occur only late in infection. However, most authors used a particular virus-cell system, allowing a high production of EEV particles to facilitate their studies (such as VV IHD-J in RK13 cells), which might have biased the outcome (in this study, we have only used one strain of FWPV and would, therefore, be wary about extending our conclusions to generalize about the morphogenesis of other strains of FWPV). Wrapping is not the only way VV uses to exit the cell (Tsutsui, 1983 ; Tsutsui et al., 1983) and might not be the only or predominant mechanism of production of EEV in most cell types and particularly in vivo. Substantial EEV production by different deletion mutants inhibiting wrapping supports the use of an alternative mechanism (Blasco & Moss, 1991 Rottger et al., 1999) .
As FWPV replicates only in avian cells, we chose to study FWPV production on CEFs and used, as a control, a VV WR recombinant virus, a low producer of EEV, grown on the same cell type. VV EEV production had been shown to be affected by several drugs inhibiting wrapping -IMCBH, glucosamine, monensin and brefeldin A -but none of them affected specifically FWPV EV production. IMCBH had been shown to inhibit specifically the production of VV EEV particles. This effect is characterized by its variable efficacy depending on the virus strain and the host cell type (Kato et al., 1969 ; Payne & Kristenson, 1979) . We showed that VV WR, a poor EEV producer, when grown on CEFs, is also sensitive to IMCBH whereas FWPV FP9 strain is not, even in a highly sensitive ' low m.o.i. ' experiment. A single amino acid in the VV F13L gene product has been shown to be critical for the effect of IMCBH. This residue is not conserved in FWPV, possibly explaining the lack of effect of IMCBH on FWPV EV production (unless FWPV is not sensitive to this drug because it uses predominantly budding instead of wrapping). However, the degree of homology between VV and FWPV F13L is relatively low and other residue substitutions or a different conformation of the protein could be responsible for the observed resistance. Further studies involving mutagenesis would need to be performed to address that question.
Glucosamine also did not affect FWPV production, whereas VV production was reduced in the presence of 20 mM glucosamine (CAV production being affected as much as EV production). This is in contrast with the results published by Payne & Kristensson (1982 b) , who used the VV IHD-J strain in RK-13 cells, and showed that the production of infectious intracellular virus was less sensitive to the presence of glycosylation inhibitors than was the production of infectious EV. Despite its overall effect on the cell metabolism, monensin did not affect either FWPV nor VV EV production, suggesting that neither O-glycosylation nor the three-dimensional structure of the Golgi compartment are essential for FWPV and VV egress in CEFs. The lack of effect of monensin on VV production is also in contrast with the results published by . This discrepancy between our results and previously published data could be explained by the use of another VV strain or more likely of another cell type.
GIC
Brefeldin A did not have any effect either on FWPV or VV EV production in CEFs. These results with VV are also in contradiction with previously published data (Ulaeto et al., 1995) , which showed a 3 log "! reduction in the EEV titre of IHD-J, grown for 24 h on RK-13 cells in the presence of 100 ng\ml of brefeldin A. However, in our system (CEFs), brefeldin A at a concentration higher than 10 ng\ml was cytotoxic. Uninfected cell morphology changed after 8 h incubation with brefeldin A, finally resulting in a CPE. Tooze et al. (1993) investigated, by electron microscopy, the wrapping of both human cytomegalovirus (HCMV) and VV WR strain, showing that wrapping was not inhibited by brefeldin A. As brefeldin A affects the Golgi but not the tubular compartment, the authors concluded that the wrapping membranes do not originate from the TGN but from the tubular endosomal compartment. However, wrapping of HCMV was affected by the drug after 3 or 4 h, resulting in an accumulation of unenveloped cytoplasmic nucleocapsids, probably due to a depletion of the pool of endosomal membranes and proteins that usually transit through the Golgi. This supports both the toxic effect of brefeldin A to CEFs in our experiments and could explain the effect on VV EEV production observed by Ulaeto et al. (1995) after a 24 h incubation in the presence of the drug.
In summary, none of the wrapping inhibitors tested, with the exception of IMCBH, had any specific effect on VV WR EV production in CEFs. This shows how important the virus strain GIE and cell type are for this kind of study, a consideration which also applies to this study, as only one strain of FWPV has been considered and only in CEFs. The lack of specific effect of the drugs (glucosamine, monensin and brefeldin A) on the VV control in our experimental conditions also rules out the use of these inhibitors to study the FWPV egress mechanism in CEFs as the results do not allow us to compare both systems and to draw any definite conclusion on FWPV exit mechanism. We can only conclude that those drugs have no effect on the morphogenesis and exit of the FP9 strain of FWPV in CEFs.
The effect of cytochalasin D on the release of VV EEV particles has been confirmed and extended to FWPV EEV production. Cytochalasin D inhibited the release of CEV particles from the surface of the cell, suggesting that actin is essential for this last step in the release of extracellular particles. The co-localization of actin with viral particles (Fig. 7 C) and the presence of filaments underneath budding particles (Fig. 2 B) argues in favour of this hypothesis. These structures are, however, quite short and differ from the long actin tails observed in VV-infected cells. Several viruses have been shown to bud through the plasma membrane by a mechanism involving actin microfilaments. The iridivirus frog virus 3 induces the formation of actin-containing projections from which the virions bud (Murti & Goorha, 1983) . Cytochalasin B and D inhibit the release of EV and lead to an accumulation of intracellular virus just beneath the cell surface (Murti et al., 1985) . Cytochalasin also inhibits the release of measles virus, which buds through the plasma membrane in close association with actin filaments (Bohn et al., 1986) , leading to an accumulation of nucleocapsids in the cytoplasm, and of mammalian B-and C-type retroviruses which bud from the cell on the tip of an actin-rich microvillus [reviewed in Sanders & Theriot (1996) and Cudmore et al. (1997) ]. In the case of FWPV, cytochalasin D does not inhibit budding, as CEV particles are produced, as for VV. Actin filaments seem therefore to be involved in the exit of FWPV and of VV, probably by two different mechanisms, but, in both cases, cytochalasin D only inhibits the release of CEV from the cell surface and does not inhibit the formation of these particles. This effect of cytochalasin D had been interpreted by as the requirement for cell movement to liberate CEV particles from the cell surface. The A34R protein, a homologue of animal C type lectins, has been shown to be involved in the retention of VV CEV particles on the cell surface (Blasco et al., 1993 ; McIntosh & Smith, 1996) ; it is not known, however, whether the A34R protein is involved directly or indirectly in this process. Actin has been shown to be linked through the ERM (ezrin, radixin, moesin) protein family to the integral membrane protein CD44 (Tsukita et al., 1994) , which is highly glycosylated and, therefore, could be a potential ligand for A34R if this protein is really a lectin. Another hypothesis for the effect of cytochalasin D would be that this drug would disrupt the interaction between actin and its membrane linker or ligand, destabilizing the interaction between the virus particles and the cell surface. The liberation of CEV particles by trypsin also argues in favour of a protein-protein interaction.
In addition to its role in the release of FWPV particles from the cell, our results indicate that actin may play an earlier role in FWPV morphogenesis, not observed in VV-infected cells (Meyer et al., 1981) , as it co-localizes with the FWPV virus factories.
